A nonlinear mixed effects IVIVC model for multi-release drug delivery systems

被引:10
作者
Rossenu, S. [1 ]
Gaynor, C. [2 ]
Vermeulen, A. [1 ]
Cleton, A. [3 ]
Dunne, A. [2 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Div Janssen Pharmaceut NV, Beerse, Belgium
[2] Univ Coll Dublin, UCD Sch Math Sci, Dublin 4, Ireland
[3] Pfizer, Sandwich, Kent, England
关键词
dissolution; in vitro/in vivo correlation; population pharmacokinetics; controlled release;
D O I
10.1007/s10928-008-9095-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this analysis was the development of an IVIVC model, which involves a convolution step as described by O'Hara et al. and to describe a dual-release system: a controlled release formulation, which contains an initial immediate release element. Four formulations of Galantamine((R)) were used to test this modelling technique and a level A IVIVC, which meets the FDA criteria for internal and external validation, was successfully developed.
引用
收藏
页码:423 / 441
页数:19
相关论文
共 19 条
[1]  
Beal SL., 1989, NONMEM 7 4 USERS GUI
[2]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[3]  
DUNNE A, 2005, CLIN RES REGUL AFF, V22, P1, DOI [DOI 10.1081/CRP-200054957, 10.1081/CRP-54957]
[4]  
Gibaldi M, 1982, Pharmacokinetics, V15
[5]  
Gillespie WR, 1997, ADV EXP MED BIOL, V423, P53
[6]   METHODS OF EXPRESSING DISSOLUTION RATE DATA [J].
GOLDSMITH, JA ;
RANDALL, N ;
ROSS, SD .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1978, 30 (06) :347-349
[7]  
Johnson N., 1994, CONTINUOUS UNIVARIAT, V1, DOI DOI 10.1016/0167-9473(96)90015-8
[8]   Pharmacokinetics and metabolism of galanthamine [J].
Kewitz, H .
DRUGS OF TODAY, 1997, 33 (04) :265-272
[9]  
Kharkevich D. A., 1986, HDB EXPT PHARM, P653
[10]   LINEARIZATION OF DISSOLUTION RATE CURVES BY WEIBULL DISTRIBUTION [J].
LANGENBUCHER, F .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1972, 24 (12) :979-+